A standardized team-based approach for identifying naloxone-eligible patients in a grocery store pharmacy

Sexton, Scott M.; Armstrong, Anna Torrens; Gatton, Ouita Davis; Rhodes, Laura A.; Marciniak, Macary Weck

doi:10.1016/j.japh.2019.03.015

Cited by 12 publications

(28 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Another two studies demonstrated a lack of understanding of cases in which naloxone is clinically appropriate [ 45 , 63 ]. Both showcased a lack of understanding with respect to the existence of a minimum age requirement [ 35 , 45 ], while one of them further demonstrated confusion regarding naloxone’s appropriateness in pregnancy or in patients who are undergoing an alcohol or barbiturate overdose [ 63 ]. Counselling knowledge gaps existed for topics such as when to call 9-1-1 when witnessing an overdose and placing the patient in the recovery position [ 63 ].…”

Section: Resultsmentioning

confidence: 99%

“… - Pharmacist reviews the screening results and provides patient-specific education and interventions using a clinical decision-making triage tool - Potential interventions can include counselling on (1) dispensing of naloxone, (2) substance use disorder, (3) referral to community support services, (4) partial fill of opioid prescription, (5) and providing pharmacy medication disposal. Sexton [ 35 ] 2019 USA Patients at risk of opioid overdose Intervention study I: Standardized team-based approach to identify naloxone-eligible persons. C1: Standard practice at control store.…”

Section: Embase Search Strategy (Performed 1 June 2020)mentioning

confidence: 99%

See 1 more Smart Citation

What Is Known about Community Pharmacy-Based Take-Home Naloxone Programs and Program Interventions? A Scoping Review

2021

View full text Add to dashboard Cite

A variety of new sources describing community pharmacy-based take-home naloxone (THN) programs have emerged recently in the literature. There is a need to define the types of take-home naloxone programs being offered to support future research designs in implementing and evaluating standardized programs that fill pharmacist and patient knowledge gaps and lift current barriers for optimal community pharmacy naloxone provision. The objective of this paper is to summarize the literature on community pharmacy-based THN programs, including specific program interventions used to increase naloxone dispensing, naloxone availability and dispensing patterns, facilitators and barriers for the THN programs, and knowledge gaps. Online databases such as PubMed, EMBASE, Scopus, and International Pharmaceutical Abstracts (IPA) and a search of the grey literature were used to identify eligible sources. Sources were screened by two reviewers for eligibility in COVIDENCE software. Both reviewers compared screening results and resolved conflicts through discussion. A data extraction form for all identified full texts was completed by both reviewers and results were compiled through reviewer discussion. Fifty-two sources met the eligibility criteria. The top three barriers identified were: cost/coverage of naloxone, stigma, and education/training for pharmacists. THN program interventions included screening tools, checklists, pocket cards, patient brochures, and utilizing the pharmacy management system to flag eligible patients. Patient knowledge gaps included naloxone misinformation and lack of awareness, while pharmacists demonstrated administrative, clinical, and counselling knowledge gaps. Naloxone availability was found to be highly variable, where independent and rural pharmacies were less likely to stock or dispense naloxone. Further, pharmacies located in districts with higher rates of opioid overdose deaths and lower household income were also less likely to have naloxone available. This review identified multiple new programs, showcasing that the implementation and evaluation of THN programs are an expanding area of research. Future research should focus on implementing and evaluating a THN program through a randomized controlled trial design that incorporates solutions for the barriers and knowledge gaps identified in this study.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Embase Search Strategy (Performed 1 June 2020)mentioning

confidence: 99%

What Is Known about Community Pharmacy-Based Take-Home Naloxone Programs and Program Interventions? A Scoping Review

2021

View full text Add to dashboard Cite

show abstract

“…57 A rapidly growing body of research explores the role of pharmacists in naloxone distribution and education across numerous practice settings. 34,[55][56][57][58][59][60] Pharmacist involvement in these programs has ranged (2012), with related inpatient charges increasing to $15 billion. 61 Access to sterile syringes has the potential to curb these increasing rates of preventable illness and expense.…”

Section: Overdose Education and Naloxone Distributionmentioning

confidence: 99%

“…A rapidly growing body of research explores the role of pharmacists in naloxone distribution and education across numerous practice settings 34,55‐60 . Pharmacist involvement in these programs has ranged from program development and provider training to patient identification and education.…”

Section: Harm Reductionmentioning

confidence: 99%

Mobilizing pharmacists to address the opioid crisis: A joint opinion of the ambulatory care and adult medicine practice and research networks of the American College of Clinical Pharmacy

Coon

Hill

Hutchison³

et al. 2020

J Am Coll Clin Pharm

View full text Add to dashboard Cite

The opioid crisis represents one of the largest failures of our current health care system as it continues to claim lives at an unprecedented rate and has caused a devastating range of preventable morbidity. Although the availability of highly potent synthetic opioids has amplified the urgency of the crisis for patients and communities, this problem has evolved over several decades. Pharmacists are in a position to offer many potential solutions due to their widespread accessibility, extensive drug knowledge, and integration into various health care settings. This opinion paper challenges the status quo by calling on all pharmacists to embrace evidence‐based opioid stewardship and harm reduction practices, contribute to the medical management of opioid use disorder, and address the misconceptions and prejudices that serve as barriers to effective, compassionate patient care. Regardless of practice setting or available resources, pharmacists can take deliberate and impactful steps to address the opioid crisis. Some pharmacists may be positioned to implement innovative and far‐reaching pharmacist‐led clinical services, while others may simply begin with careful consideration of the language they use when speaking to and about patients with substance use disorders. To optimize patient outcomes, the ineffective laws, regulations, and policies that negatively impact pain and addiction care must be addressed so that evidence‐based solutions can be widely disseminated. Pharmacists must aggressively advocate for the removal of barriers preventing high‐level clinical practice or policies that perpetuate patient harm and abandonment. Finally, there must be support for continued research on pain and opioid use disorder treatments and services, as well as the impacts of harm reduction practices and pharmacist‐led clinical services, so that resources can be allocated effectively.

show abstract

“…Many pharmacists have recognized this position and pharmacy-based programs to address the opioid crisis have been initiated. Identifying naloxone-eligible patients and implementation of naloxone distribution programs are 2 examples 8,9 A recent analysis of state-level changes related to naloxone-dispensing laws revealed that the states that granted direct authority to pharmacists to provide naloxone saw significant reductions in fatal opioid overdoses, whereas the other states did not. 10 Programs that go beyond naloxone distribution and incorporate multipronged pharmacist-led approaches to reducing opioid risk, including increasing availability of medication take-back locations and focused patient education, have also been described.…”

mentioning

confidence: 99%

Implementation of a statewide program within community pharmacies to prevent opioid misuse and accidental overdose

Skoy¹,

Eukel²,

Werremeyer³

et al. 2020

Journal of the American Pharmacists Association

View full text Add to dashboard Cite

A standardized team-based approach for identifying naloxone-eligible patients in a grocery store pharmacy

Cited by 12 publications

References 6 publications

What Is Known about Community Pharmacy-Based Take-Home Naloxone Programs and Program Interventions? A Scoping Review

What Is Known about Community Pharmacy-Based Take-Home Naloxone Programs and Program Interventions? A Scoping Review

Mobilizing pharmacists to address the opioid crisis: A joint opinion of the ambulatory care and adult medicine practice and research networks of the American College of Clinical Pharmacy

Implementation of a statewide program within community pharmacies to prevent opioid misuse and accidental overdose

Contact Info

Product

Resources

About